Rasko J E, Begley C G
Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Parkville, Victoria, Australia.
Int J Biochem Cell Biol. 1998 Jun;30(6):657-60. doi: 10.1016/s1357-2725(97)00148-9.
Mpl-ligand (thrombopoietin [TPO] or Megakaryocyte growth and development factor [MGDF]), was identified following the discovery of the oncogene, mpl. This oncogene encodes a truncated receptor belonging to the hemopoietin-receptor superfamily. Mpl-ligand consists of two domains; a carbohydrate-rich domain and an amino-terminal domain which displays homology to erythropoietin and is fully active. Mpl-ligand mRNA is predominantly expressed in liver and kidney and plasma levels are regulated by receptors expressed on megakaryocytes and platelets. Mpl-ligand is the most active single agent capable of promoting proliferation and maturation of cells within the megakaryocyte lineage. In addition to this 'lineage-specific' action, Mpl-ligand also acts on progenitor/stem cells of multiple hemopoietic lineages. Pre-clinical and early clinical studies have demonstrated the ability of Mpl-ligand to increase platelet counts and hasten platelet recovery after chemotherapy. This offers considerable promise for its use in clinical oncology.
Mpl配体（血小板生成素[TPO]或巨核细胞生长与发育因子[MGDF]）是在癌基因mpl被发现后确定的。该癌基因编码一种属于血细胞生成素受体超家族的截短受体。Mpl配体由两个结构域组成；一个富含碳水化合物的结构域和一个与促红细胞生成素具有同源性且具有完全活性的氨基末端结构域。Mpl配体mRNA主要在肝脏和肾脏中表达，血浆水平受巨核细胞和血小板上表达的受体调节。Mpl配体是能够促进巨核细胞系内细胞增殖和成熟的最具活性的单一因子。除了这种“谱系特异性”作用外，Mpl配体还作用于多个造血谱系的祖细胞/干细胞。临床前和早期临床研究已证明Mpl配体具有增加化疗后血小板计数和加速血小板恢复的能力。这为其在临床肿瘤学中的应用带来了巨大希望。
